Involvement of GABAB receptors in the motor inhibition produced by agonists of brain cannabinoid receptors

Behavioural Pharmacology

Volumn 7, Issue 3, 1996, Pages 299-302

  Romero, J ^a   Garcia Palomero E ^a   Fernandez Ruiz J J ^a   Ramos, J A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Anandamide (arachidonylethanolamide); Cannabinoid receptors; GABAB receptors; GABAergic neurons; Motor behavior; Rat; 9 tetrahydrocannabinol

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ANANDAMIDE; BACLOFEN; CANNABINOID RECEPTOR AGONIST; DRONABINOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; GABAERGIC TRANSMISSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; RAT;

EID: 0029931386     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199605000-00011     Document Type: Article

References (16)

1. Banerjee SP, Snyder SH and Mechoulam R (1975) Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. Journal of Pharmacology and Experimental Therapeutics, 194, 74-81.
2. B binding sites in rat central nervous system: a quantitative autoradiographic study. Neuroscience, 34, 341-357.
3. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane W and Axelrod J (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology Biochemistry and Behavior, 46, 967-972.
4. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
5. Fride E and Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology, 231, 313-314.
6. Herkenham M, Lynn AB, de Costa BR and Richfield EK (1991b) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research, 547, 267-274.
7. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR and Herkenham M (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends in Neurosciences, 13, 420-423.
8. 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacology Biochemistry and Behavior, 45, 291-298.
9. B receptors. European Journal of Pharmacology, 187, 27-38.
10. Paredes R and Agmo A (1992) GABA and behavior: the role of receptor subtypes. Neuroscience and Biobehavioral Reviews, 16, 145-170.
11. 9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology, 27, 1256-1270.
12. 8-tetrahydrocannabinol reduces the turnover rate of gamma-aminobutiric acid in the septum and nucleus accumbens. Life Sciences, 30, 1841-1846.
13. Romero J García L, Cebeira M, Zadrozny D, Fernández-Ruiz JJ and Ramos JA (1995a) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sciences, 56, 2033-2040.
14. Romero J, de Miguel R, García-Palomero E, Fernández-Ruiz JJ and Ramos JA (1995b) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Research, 694, 223-232.
15. A receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. Journal of Neuroscience, 15, 3092-3103.
16. 9-tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. European Journal of Pharmacology, 250, 205-208.